CN Patent

CN117771363A — 治疗癌症的卡博替尼与阿特珠单抗组合

Assigned to Exelixis Inc · Expires 2024-03-29 · 2y expired

What this patent protects

本发明涉及卡博替尼与阿特珠单抗的组合，用于治疗局部晚期或转移性实体肿瘤，特别是晚期尿路上皮癌或肾细胞癌。

USPTO Abstract

本发明涉及卡博替尼与阿特珠单抗的组合，用于治疗局部晚期或转移性实体肿瘤，特别是晚期尿路上皮癌或肾细胞癌。

Drugs covered by this patent

Patent Metadata

Patent number
CN117771363A
Jurisdiction
CN
Classification
—
Expires
2024-03-29
Drug substance claim
No
Drug product claim
No
Assignee
Exelixis Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.